AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32475914 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic drug use (including benzodiazepine receptor agonists)
Number of subjects: 111
Study 32475914 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine receptor agonists
Number of subjects: 111
Study 32475914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon
Number of subjects: 111
Study 32475914 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 111
Study 36319696 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (n = 33) comprising mixed‐chain length oligosaccharides and nine microbial strains
Number of subjects: 64
Study 36319696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 64
Study 34580640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Number of subjects: 50
Study 34580640 — intervention group
Group type: COMPARATOR
Intervention: Standard care after CABG
Number of subjects: 50
Study 33028256 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring
Number of subjects: 0
Study 33028256 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 0
Study 33028256 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Number of subjects: 0
Study 34647795 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (10 mg/mL dipalmitoylphosphatidylcholine; DPPC)
Number of subjects: 16
Study 34647795 — intervention group
Group type: COMPARATOR
Intervention: Saline-based liquid aerosols
Number of subjects: 16
Study 34288546 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. high-dose furosemide plus HSS
Number of subjects: 141
Study 34288546 — intervention group
Group type: COMPARATOR
Intervention: furosemide alone
Number of subjects: 141
Study 33506455 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNB alone
Number of subjects: 235
Study 33506455 — intervention group
Group type: COMPARATOR
Intervention: EUS-FNA+ROSE
Number of subjects: 235
Study 34016662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) during lower-leg immobilisation
Number of subjects: 700
Study 34016662 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 700
Study 34016662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 700
Study 33326634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional micro‐plasma RF
Number of subjects: 60
Study 33326634 — intervention group
Group type: COMPARATOR
Intervention: Fractional microneedle RF
Number of subjects: 60
Study 34785310 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with VMT
Number of subjects: 30
Study 34785310 — intervention group
Group type: COMPARATOR
Intervention: Control group (VMT only)
Number of subjects: 30
Study 33162300 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with heart failure (HF)
Number of subjects: 355
Study 32682554 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced auditory display (varying pitch plus tremolo and acoustic brightness)
Number of subjects: 20
Study 32682554 — intervention group
Group type: COMPARATOR
Intervention: Standard auditory display (varying pitch plus alarm)
Number of subjects: 20
Study 32682554 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced auditory display
Number of subjects: 20
Study 32682554 — intervention group
Group type: COMPARATOR
Intervention: Standard auditory display
Number of subjects: 20
Study 35221140 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction stereotactic ablative body radiotherapy (SABR)
Number of subjects: 0
Study 35221140 — intervention group
Group type: COMPARATOR
Intervention: Multi-fraction SABR regimens
Number of subjects: 0
Study 33888528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose erythropoietin
Number of subjects: 0
Study 33888528 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and MRS biomarkers
Number of subjects: 0
Study 34042314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenebrutinib 150 mg once daily
Number of subjects: 260
Study 34042314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenebrutinib 200 mg twice daily
Number of subjects: 260
Study 34042314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 34042314 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenebrutinib (both dosages)
Number of subjects: 260
Study 32479750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 62.5 mg twice daily
Number of subjects: 106
Study 32479750 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide 125 mg twice daily
Number of subjects: 106
Study 32479750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 35304395 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC)
Number of subjects: 0
Study 35304395 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 0
Study 33439695 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month treatment (CAPOX or FOLFOX)
Number of subjects: 3273
Study 33439695 — intervention group
Group type: COMPARATOR
Intervention: 6-month treatment (CAPOX or FOLFOX)
Number of subjects: 3273
Study 33439695 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX (3-month or 6-month)
Number of subjects: 3273
Study 33439695 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (3-month or 6-month)
Number of subjects: 3273
Study 34996794 — intervention group
Group type: COMPARATOR
Intervention: Information condition (usual care)
Number of subjects: 0
Study 34996794 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation condition
Number of subjects: 0
Study 34996794 — intervention group
Group type: EXPERIMENTAL
Intervention: Action condition
Number of subjects: 0
Study 34996794 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 0
Study 32654257 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated phone intervention (self-scheduling text or phone message)
Number of subjects: 278
Study 32654257 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care written instructions (control)
Number of subjects: 278
Study 36445663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglion plexus (GP) ablation
Number of subjects: 204
Study 36445663 — intervention group
Group type: COMPARATOR
Intervention: No GP ablation
Number of subjects: 204
Study 36445663 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 204
Study 32770531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose (180 mg)
Number of subjects: 30
Study 35850739 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic to measure reactive dynamic balance
Number of subjects: 450
Study 35850739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive testing in the gait laboratory
Number of subjects: 450
Study 35850739 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group interviews
Number of subjects: 450
Study 32037209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold sterilization (glutaraldehyde)
Number of subjects: 120
Study 32037209 — intervention group
Group type: COMPARATOR
Intervention: Hot sterilization (autoclave)
Number of subjects: 120
Study 32037209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Organizers brand
Number of subjects: 120
Study 32037209 — intervention group
Group type: EXPERIMENTAL
Intervention: American Orthodontics brand
Number of subjects: 120
Study 32037209 — intervention group
Group type: EXPERIMENTAL
Intervention: SIA brand
Number of subjects: 120
Study 32037209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestenco brand
Number of subjects: 120
Study 36441270 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA plus CGF membrane
Number of subjects: 30
Study 36441270 — intervention group
Group type: COMPARATOR
Intervention: DFDBA alone (control group)
Number of subjects: 30
Study 33632264 — intervention group
Group type: EXPERIMENTAL
Intervention: HETROM-2.5 (2.5 mg hetrombopag once daily)
Number of subjects: 0
Study 33632264 — intervention group
Group type: EXPERIMENTAL
Intervention: HETROM-5 (5 mg hetrombopag once daily)
Number of subjects: 0
Study 33632264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33963089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk exclusion diet for the first 4 months of life
Number of subjects: 487
Study 33963089 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya milk preparation offered to intervention group
Number of subjects: 487
Study 33963089 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (control)
Number of subjects: 487
Study 33963089 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier exposure to soya milk
Number of subjects: 487
Study 33963089 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeze
Number of subjects: 487
Study 33261155 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg group (2 eggs for breakfast 5 days per week)
Number of subjects: 110
Study 33261155 — intervention group
Group type: COMPARATOR
Intervention: Cereal group (breakfast cereal)
Number of subjects: 110
Study 33261155 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg group
Number of subjects: 110
Study 33261155 — intervention group
Group type: COMPARATOR
Intervention: Cereal group
Number of subjects: 110
Study 33261155 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg group (post-hoc analysis of obese participants)
Number of subjects: 110
Study 33261155 — intervention group
Group type: COMPARATOR
Intervention: Cereal group (post-hoc analysis of obese participants)
Number of subjects: 110
Study 33261155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 34018237 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Oral health text messages
Number of subjects: 150
Study 34018237 — intervention group
Group type: COMPARATOR
Intervention: Standard dental leaflets
Number of subjects: 150
Study 33762086 — intervention group
Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 165
Study 33762086 — intervention group
Group type: COMPARATOR
Intervention: Weight Loss (WL)
Number of subjects: 165
Study 33762086 — intervention group
Group type: COMPARATOR
Intervention: Metformin (M)
Number of subjects: 165
Study 32754748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SRL (lanreotide 120 mg/octreotide long-acting release [LAR] 30 mg) plus weekly pegvisomant (40-160 mg/week)
Number of subjects: 60
Study 32754748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SRL (lanreotide 60 mg/octreotide LAR 10 mg) plus weekly pegvisomant
Number of subjects: 60
Study 32754748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SRL plus daily pegvisomant (15-60 mg/day)
Number of subjects: 60
Study 32754748 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SRL (lanreotide 120 mg/octreotide LAR 30 mg) plus weekly pegvisomant (40-160 mg/week)
Number of subjects: 60
Study 35266670 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading and under-drilling
Number of subjects: 44
Study 35266670 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading and complete drilling
Number of subjects: 44
Study 35266670 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading and under-drilling
Number of subjects: 44
Study 35266670 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading and complete drilling
Number of subjects: 44
Study 35381609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestational DM
Number of subjects: 5436
Study 35381609 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 5436
Study 35381609 — intervention group
Group type: COMPARATOR
Intervention: Control group (without DM)
Number of subjects: 5436
Study 33417306 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model using molecular descriptors as drug structure information
Number of subjects: 380
Study 36130765 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual mobility THA
Number of subjects: 1536
Study 36130765 — intervention group
Group type: COMPARATOR
Intervention: Conventional THA
Number of subjects: 1536
Study 34933737 — intervention group
Group type: EXPERIMENTAL
Intervention: AgNPs
Number of subjects: 0
Study 32118256 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 5929
Study 32118256 — intervention group
Group type: COMPARATOR
Intervention: No reperfusion therapy (Control)
Number of subjects: 5929
Study 35469330 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administration
Number of subjects: 0
Study 35469330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32220091 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISMS form (intervention group)
Number of subjects: 202
Study 32220091 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 202
Study 33640444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 mcg/kg
Number of subjects: 120
Study 33640444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 mcg/kg
Number of subjects: 120
Study 33640444 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study 34110581 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent health behavioral intervention delivered through teachers
Number of subjects: 0
Study 32681463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives containing Cyproterone Acetate (CPA)
Number of subjects: 120
Study 32681463 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives containing Levonorgestrel (LNG)
Number of subjects: 120
Study 32681463 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives containing Desogestrel (DSG)
Number of subjects: 120
Study 32681463 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives containing Drospirenone (DRSP)
Number of subjects: 120
Study 32357900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray
Number of subjects: 100
Study 32357900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 100
Study 34039690 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) with alarms set at 2.61-10 mmol/L (47-180 mg/dL)
Number of subjects: 48
Study 34039690 — intervention group
Group type: COMPARATOR
Intervention: Control group with alarms set at 3.44-7.78 mmol/L (62-140 mg/dL)
Number of subjects: 48
Study 34039690 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict protocol using CGM
Number of subjects: 48
Study 33516483 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DEX) 1.5 mg/kg of diet
Number of subjects: 96
Study 33516483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 1.5 mg/kg of diet and omega-3 fatty acids supplementation
Number of subjects: 96
Study 33516483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.48% omega-3 fatty acids
Number of subjects: 96
Study 35488238 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month diet intervention
Number of subjects: 0
Study 35488238 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise intervention
Number of subjects: 0
Study 35488238 — intervention group
Group type: COMPARATOR
Intervention: 12-month combined diet and exercise intervention
Number of subjects: 0
Study 35488238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential interventions
Number of subjects: 0
Study 35488238 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous interventions
Number of subjects: 0
Study 34508740 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron infusion (iron (III)-hydroxide sucrose; 200mg)
Number of subjects: 46
Study 34508740 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 46
Study 34734227 — intervention group
Group type: EXPERIMENTAL
Intervention: STRSI-guided LV lead positioning
Number of subjects: 172
Study 34734227 — intervention group
Group type: COMPARATOR
Intervention: Conventional implantation (Control)
Number of subjects: 172
Study 34734227 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 172
Study 33359908 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral quadratus lumborum block (QLB)
Number of subjects: 0
Study 33359908 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 0
Study 32105093 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders to avoid safety behaviors (SBs)
Number of subjects: 94
Study 32105093 — intervention group
Group type: COMPARATOR
Intervention: Present-focused text message condition
Number of subjects: 94
Study 35078150 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-myofascial release program (FOAM) 3 times per week for 8 weeks
Number of subjects: 24
Study 35078150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 33633408 — intervention group
Group type: EXPERIMENTAL
Intervention: OAS1 levels (increased)
Number of subjects: 14134
Study 32723088 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais method
Number of subjects: 60
Study 32723088 — intervention group
Group type: COMPARATOR
Intervention: Control (core stability exercises)
Number of subjects: 60
Study 33278048 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia implant under experimental mucositis conditions (Zr-m)
Number of subjects: 42
Study 33278048 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium implant under experimental mucositis conditions (Ti-m)
Number of subjects: 42
Study 33278048 — intervention group
Group type: COMPARATOR
Intervention: Zirconia implant under healthy conditions (Zr-h)
Number of subjects: 42
Study 33278048 — intervention group
Group type: COMPARATOR
Intervention: Titanium implant under healthy conditions (Ti-h)
Number of subjects: 42
Study 32338104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalomedullary nailing
Number of subjects: 50
Study 32338104 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold value of fracture height
Number of subjects: 50
Study 34903479 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 320
Study 34903479 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 320
Study 34903479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular mortality
Number of subjects: 320
Study 34903479 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure hospitalizations
Number of subjects: 320
Study 32503949 — intervention group
Group type: EXPERIMENTAL
Intervention: TPIV200 and durvalumab
Number of subjects: 27
Study 35342642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise programme using rubber bands and stretching
Number of subjects: 579
Study 35342642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 579
Study 32683477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Q-angle gait pattern during normal walking in patients with chronic patellofemoral instability
Number of subjects: 35
Study 32683477 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral antetorsion (femAT)
Number of subjects: 35
Study 32683477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial tubercle-trochlear groove (TT-TG) distance
Number of subjects: 35
Study 32683477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic valgus in a single-leg squat
Number of subjects: 35
Study 32683477 — intervention group
Group type: EXPERIMENTAL
Intervention: Static measured Q-angle
Number of subjects: 35
Study 32683477 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg's sign
Number of subjects: 35
Study 35916813 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.2 g PHGG daily for 12 weeks
Number of subjects: 96
Study 32998756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total hip replacement (CTR)
Number of subjects: 268
Study 32998756 — intervention group
Group type: COMPARATOR
Intervention: Uncemented total hip replacement (UTR)
Number of subjects: 268
Study 36461909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking program (>7500 steps/day for 5 days/week) plus resistance exercise (elastic band, twice/week)
Number of subjects: 90
Study 36461909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 36461909 — intervention group
Group type: COMPARATOR
Intervention: Interaction effect between intervention and control groups
Number of subjects: 90
Study 32736036 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience at 6 weeks after surgery
Number of subjects: 248
Study 32736036 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy at 6 weeks after surgery
Number of subjects: 248
Study 32053158 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib
Number of subjects: 0
Study 32053158 — intervention group
Group type: COMPARATOR
Intervention: Medicare Beneficiaries
Number of subjects: 0
Study 34142251 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation (knee extension exercise started within 4 hours after surgery)
Number of subjects: 80
Study 34142251 — intervention group
Group type: COMPARATOR
Intervention: Control rehabilitation (knee extension exercise started 2 days after surgery)
Number of subjects: 80
Study 35122820 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 BC: 00 FYM (sole biochar)
Number of subjects: 0
Study 35122820 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 BC: 25 FYM
Number of subjects: 0
Study 35122820 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 BC: 50 FYM
Number of subjects: 0
Study 35122820 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 BC: 75 FYM
Number of subjects: 0
Study 35122820 — intervention group
Group type: EXPERIMENTAL
Intervention: 00 BC: 100 FYM
Number of subjects: 0
Study 35122820 — intervention group
Group type: COMPARATOR
Intervention: 00 BC: 00 FYM
Number of subjects: 0
Study 33754800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular allogenic lyophilized growth factors (L-GFs), two doses at baseline and after 2 months
Number of subjects: 31
Study 33754800 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 31
Study 36250945 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial limitations in physical function at baseline
Number of subjects: 2950